Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 50
- Registration Number
- NCT06745063
- Locations
- 🇺🇸
Harry S. Truman Memorial, Columbia, MO, Columbia, Missouri, United States
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Conrado Roberto Hoffmann Filho
- Target Recruit Count
- 90
- Registration Number
- NCT06683053
- Locations
- 🇧🇷
Multidisciplinary Center for Specialized Education and Research Ltd., Joinville, Santa Catarina, Brazil
Randomized Trial of SGLT2i in Heart Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 200
- Registration Number
- NCT06625073
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States
🇺🇸Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States
🇺🇸Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 16
- Registration Number
- NCT06618976
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 582
- Registration Number
- NCT06571591
- Locations
- 🇰🇷
Celltrion, Incheon, Korea, Republic of
Feasibility Trial for a Right Ventricular Failure Platform Trial
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT06570473
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11000
- Registration Number
- NCT06531824
- Locations
- 🇺🇸
Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, United States
🇩🇪Universitätsklinikum Würzburg AÖR, Würzburg, Germany
🇬🇧Churchill Hospital, Oxford, United Kingdom
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 264
- Registration Number
- NCT06528405
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 80
- Registration Number
- NCT06507657
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Cantonal Hospital Graubuenden
- Target Recruit Count
- 40
- Registration Number
- NCT06435858
- Locations
- 🇨🇭
Cantonal Hospital Graubuenden, Chur, Graubuenden, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.